This HTML5 document contains 60 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/mesh/concept/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01031/identifier/chemspider/
n20http://bio2rdf.org/drugbank:
n14http://linked.opendata.cz/resource/drugbank/drug/DB01031/identifier/chebi/
admshttp://www.w3.org/ns/adms#
n12http://linked.opendata.cz/resource/drugbank/drug/DB01031/identifier/wikipedia/
n11http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01031/identifier/pharmgkb/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n15http://linked.opendata.cz/resource/drugbank/drug/DB01031/identifier/kegg-compound/
n5http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01031/identifier/pubchem-compound/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n8http://linked.opendata.cz/resource/drugbank/drug/DB01031/identifier/pubchem-substance/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01031/identifier/kegg-drug/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01031/identifier/drugbank/

Statements

Subject Item
n2:DB01031
rdf:type
n3:Drug
n3:description
Ethinamate is a short-acting sedative-hypnotic medication used to treat insomnia. Regular use leads to tolerance, and it is usually not effective for more than 7 days. Structurally, it does not resemble the barbituates, but it shares many effects with this class of drugs; the depressant effects of ethinamate are, however, generally milder than those of most barbiturates.
n3:group
illicit approved withdrawn
n3:halfLife
2.5 hours
n3:indication
Used for the short-term treatment of insomnia, however, it generally has been replaced by other sedative-hypnotic agents.
owl:sameAs
n11:DB01031 n20:DB01031
dcterms:title
Ethinamate
adms:identifier
n8:46507468 n9:PA164745394 n12:Ethinamate n13:3284 n14:4884 n15:C07832 n16:D00703 n17:3169 n19:DB01031
n3:mechanismOfAction
The mechanism of action is not known. However, studies have shown that ethinamate inhibits carbonic anhydrases I and II (J Biol Chem. 1992 Dec 15;267(35):25044-50). This inhibition by ethinamate is not sufficiently strong, however, to implicate carbonic anhydrases I and II in the mechanism of action.
n3:synonym
Etinamato Ethinamatum 1-Ethynylcyclohexanol carbamate Ethinamate Aethinyl-cyclohexyl-carbamat
n3:toxicity
Symptoms of overdose include shortness of breath or slow or troubled breathing, slow heartbeat, severe weakness, chronic confusion, slurred speech, and staggering.
n3:synthesisReference
Junkmann, K. and Pfeiffer, H.; US. Patent 2,816,910; December 17, 1957; assigned to Schering AG, Germany.
n5:hasConcept
n6:M0262973
n3:IUPAC-Name
n4:271B5671-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5677-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5676-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5673-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5674-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5675-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5686-363D-11E5-9242-09173F13E4C5 n4:271B566F-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B566D-363D-11E5-9242-09173F13E4C5 n4:271B5689-363D-11E5-9242-09173F13E4C5 n4:271B5670-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B566E-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B567D-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B567E-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5678-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5679-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B567B-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B567A-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B567C-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly absorbed following oral administration.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
126-52-3
n3:Bioavailability
n4:271B5682-363D-11E5-9242-09173F13E4C5
n3:Boiling-Point
n4:271B5688-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5684-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5685-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5687-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5681-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5680-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5683-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5672-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B567F-363D-11E5-9242-09173F13E4C5